Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Karen C Thompson

Ashok V Katdare

Raymond J Higgins

Udit Batra

Andrew S Thompson

H William Bosch

Thomas R Verhoeven

Robert D Larsen

Louis S Crocker

Jerry Anthony Murry

Robert Wenslow

Gerald S Brenner

Elaine Liversidge

Chris H Senanayake

Russell R Ferlita

Ralph Calabria

Andrey V Peresypkin

Ashkan Kamali

Jian Wang

David Mathre

Yu Cheng

Suhas D Shelukar

Hossain Jahansouz

William H Bosch

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.

Pharmaceutical composition of a tachykinin receptor antagonist

The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.

Crystalline forms of MC4R agonist and process for synthesis

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

Compressed tablet formulation

Polymorphic forms of the angiotensin II receptor antagonist, 3-�2'-(N-benzoyl)sulfonamidobiphenyl-4-yl!methyl-5,7-dimethyl-2-ethyl-3H-i midazo�4,5-b!pyridine and a method for the preparation of these crystal forms.

Polymorphic forms of an angiotensin II antagonist

Growing community of inventors

Lansdale, PA, United States of America

Karen C Thompson